Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTMBiotechnology
+$3.42 today
- Market cap
- $8.25B
- Beta
- 1.92
- P/E (TTM)
- -33.3
- EPS (TTM)
- -$2.98
Volume 2.01M
Average 0.81M
RYTM Net Income
Bottom-line profit after all expenses, interest, and taxes.
Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income remains negative
Q3 FY2026 net income was -$41.37M, compared with -$52.9M a year earlier. Trailing-twelve-month net income was -$193.81M.
Context
- Net income amounted to 103.6% of revenue in FY2025, down 96.7 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 13 analysts of -$356.82M (-81.5%) for the fiscal year ending Dec 2026, a slowdown from the +24.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$41.37M+16.1% QoQ
- Last fiscal yearDec 2025
- -$196.54M+24.6% YoY
- LTMSep 2026
- -$193.81M-0.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.8% | -313.1% | -334.9 pp |
| 1 year | +24.6% | -81.5% | -106.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (196.54M) USD
- Year-over-year change
- +24.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (196.54M) | +24.6% |
| FY2024 | 2024-12-31 | (260.6M) | -41.1% |
| FY2023 | 2023-12-31 | (184.68M) | -2.0% |
| FY2022 | 2022-12-31 | (181.12M) | -160.2% |
| FY2021 | 2021-12-31 | (69.61M) | — |
Net Income vs competitors
How RYTM compares with its peers on the latest reported figures
- RYTM's LTM Sep 2026 net income of -$193.81M is the 8th highest of the 11 companies compared; the peer median is -$116.74M.
- Its year-over-year change of -0.8% is the 4th highest of 11, against a peer median of -52.2%.
- Net income amounts to 69.0% of revenue for RYTM, versus a peer median of 61.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$6.25M | +73.2% | — | 48.5% | |
| LTM Mar 2026 | -$44.95M | +65.1% | — | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$59M | -0.3% | — | 61.3% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.93M | -26.6% | — | 871.8% |
BLTEBelite Bio, Inc | LTM Sep 2026 | -$110.95M | -77.8% | — | — |
| LTM Mar 2026 | -$122.54M | -335.9% | — | 612.7% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$145.1M | -80.3% | — | — |
| LTM Sep 2026 | -$193.81M | -0.8% | — | 69.0% | |
| LTM Jun 2026 | -$215.06M | -20.2% | — | — | |
| LTM Jun 2026 | -$534.8M | -211.7% | — | — | |
| LTM Sep 2026 | -$122.73B | -23682.5% | +35.1% | 11.9% | |
| Peer median (excluding RYTM) | -$116.74M | -52.2% | +35.1% | 61.3% | |
Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.15M | 23.64M | 77.43M | 130.13M | 189.76M |
| Cost of Revenue | 599K | 2.13M | 9.3M | 13.37M | 19.49M |
| Gross Profit | 2.56M | 21.51M | 68.13M | 116.76M | 170.27M |
| Gross Margin | 81.0% | 91.0% | 88.0% | 89.7% | 89.7% |
| Research & Development | 104.13M | 108.63M | 134.95M | 237.96M | 167.34M |
| Selling, General & Admin | 68.49M | 92.03M | 117.53M | 144.3M | 194.94M |
| Operating Expenses | 172.61M | 200.66M | 252.48M | 382.26M | 362.28M |
| Depreciation & Amortization | 1.16M | 1.67M | 1.76M | 1.56M | 1.34M |
| EBITDA | (68.45M) | (174.25M) | (168.46M) | (238.09M) | (174.12M) |
| EBITDA Margin | -2170.4% | -737.1% | -217.6% | -183.0% | -91.8% |
| Operating Income | (170.06M) | (179.16M) | (184.36M) | (265.5M) | (192.02M) |
| Operating Margin | -5391.9% | -757.9% | -238.1% | -204.0% | -101.2% |
| Interest Income | 447K | 4.03M | 13.95M | 14.71M | 15.29M |
| Interest Expense | 0 | 5.2M | 13.89M | 20.6M | 20.58M |
| Other Income / Expenses | 100.45M | (1.96M) | 243K | 5.25M | (4.03M) |
| Income Before Tax | (69.61M) | (181.12M) | (184.11M) | (260.26M) | (196.04M) |
| Pre-Tax Margin | -2207.1% | -766.2% | -237.8% | -200.0% | -103.3% |
| Income Tax Expense | 0 | 0 | 564K | 346K | 497K |
| Net Income | (69.61M) | (181.12M) | (184.68M) | (260.6M) | (196.54M) |
| Net Margin | -2207.1% | -766.2% | -238.5% | -200.3% | -103.6% |
| EPS (Basic) | (1.37) | (3.51) | (3.20) | (4.34) | (3.11) |
| EPS (Diluted) | (1.37) | (3.51) | (3.20) | (4.34) | (3.11) |
| Weighted Avg Shares | 49.6M | 52.12M | 57.67M | 61M | 64.98M |
| Weighted Avg Shares (Diluted) | 49.6M | 52.12M | 57.67M | 61M | 64.98M |
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
Intrinsic Alpha fair value
Locked
Current Price
$119.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.